Cargando…
Integrating Network Pharmacology and Component Analysis to Study the Potential Mechanisms of Qi-Fu-Yin Decoction in Treating Alzheimer’s Disease
PURPOSE: To elucidate the potential mechanisms of QFY for the treatment of Alzheimer’s Disease (AD), and explore the effective substances of QFY. MATERIALS AND METHODS: UPLC-LTQ-Orbitrap-MS was used to identify the chemical constituents of the serum samples and the cerebrospinal fluid samples of rat...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506672/ https://www.ncbi.nlm.nih.gov/pubmed/37727255 http://dx.doi.org/10.2147/DDDT.S402624 |
_version_ | 1785107153554505728 |
---|---|
author | Lei, Xia Xu, Hongdan Wang, Yan Gao, Hainan Zhao, Deping Zhang, Jinfeng Zhu, Ziyue Zuo, Kun Liu, Ying Li, Xiaoliang Zhang, Ning |
author_facet | Lei, Xia Xu, Hongdan Wang, Yan Gao, Hainan Zhao, Deping Zhang, Jinfeng Zhu, Ziyue Zuo, Kun Liu, Ying Li, Xiaoliang Zhang, Ning |
author_sort | Lei, Xia |
collection | PubMed |
description | PURPOSE: To elucidate the potential mechanisms of QFY for the treatment of Alzheimer’s Disease (AD), and explore the effective substances of QFY. MATERIALS AND METHODS: UPLC-LTQ-Orbitrap-MS was used to identify the chemical constituents of the serum samples and the cerebrospinal fluid samples of rats after QFY administration. Network pharmacology was used to predict potential targets and pathways of QFY against AD. The AD mice model was established by subcutaneous injection of D-gal for 8 consecutive weeks. New object recognition (NOR) and Morris water maze test (MWM) were used to evaluate the learning and memory abilities of mice. Moreover, the levels of TNF-α, IL-1β, and IL-18 in the brain hippocampus of mice were determined by ELISA. The expression of Bax, Bcl-2, Caspase-1, PSD95, SYP, ICAM-1 and MCP-1 proteins in the hippocampus was detected by Western blotting. Furthermore, qRT-PCR was used to detect the gene expressions of PSD95, SYP, M1 and M2 polarization markers of microglia, including iNOS, CD16, ARG-1, and IL-10 in the hippocampus. RESULTS: A total of 51 prototype compounds were detected in rat serum and 15 prototype components were identified in rat cerebrospinal fluid. Behavioral experiments revealed that QFY significantly increased the recognition index, decreased the escape latency, increased the platform crossing times and increased the residence time in the target quadrant. QFY also could alleviate the ultrastructural pathological changes in the hippocampus of AD mice. Meanwhile, QFY treatment suppressed the expression of inflammatory factors, such as TNF-α, IL-1β, and IL-18. QFY improved the synaptic plasticity of the hippocampus in D-gal model mice by significantly increasing the expression of proteins and mRNAs of PSD95 and SYP. CONCLUSION: QFY could effectively improve the learning and memory impairment of D-gal-induced AD mice by inhibiting the excessive activation of microglia, enhancing the expression of M2 microglia, inhibiting the increase of inflammatory factors, cell adhesion factors and chemokines, anti-apoptosis, and improving synaptic plasticity. |
format | Online Article Text |
id | pubmed-10506672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105066722023-09-19 Integrating Network Pharmacology and Component Analysis to Study the Potential Mechanisms of Qi-Fu-Yin Decoction in Treating Alzheimer’s Disease Lei, Xia Xu, Hongdan Wang, Yan Gao, Hainan Zhao, Deping Zhang, Jinfeng Zhu, Ziyue Zuo, Kun Liu, Ying Li, Xiaoliang Zhang, Ning Drug Des Devel Ther Original Research PURPOSE: To elucidate the potential mechanisms of QFY for the treatment of Alzheimer’s Disease (AD), and explore the effective substances of QFY. MATERIALS AND METHODS: UPLC-LTQ-Orbitrap-MS was used to identify the chemical constituents of the serum samples and the cerebrospinal fluid samples of rats after QFY administration. Network pharmacology was used to predict potential targets and pathways of QFY against AD. The AD mice model was established by subcutaneous injection of D-gal for 8 consecutive weeks. New object recognition (NOR) and Morris water maze test (MWM) were used to evaluate the learning and memory abilities of mice. Moreover, the levels of TNF-α, IL-1β, and IL-18 in the brain hippocampus of mice were determined by ELISA. The expression of Bax, Bcl-2, Caspase-1, PSD95, SYP, ICAM-1 and MCP-1 proteins in the hippocampus was detected by Western blotting. Furthermore, qRT-PCR was used to detect the gene expressions of PSD95, SYP, M1 and M2 polarization markers of microglia, including iNOS, CD16, ARG-1, and IL-10 in the hippocampus. RESULTS: A total of 51 prototype compounds were detected in rat serum and 15 prototype components were identified in rat cerebrospinal fluid. Behavioral experiments revealed that QFY significantly increased the recognition index, decreased the escape latency, increased the platform crossing times and increased the residence time in the target quadrant. QFY also could alleviate the ultrastructural pathological changes in the hippocampus of AD mice. Meanwhile, QFY treatment suppressed the expression of inflammatory factors, such as TNF-α, IL-1β, and IL-18. QFY improved the synaptic plasticity of the hippocampus in D-gal model mice by significantly increasing the expression of proteins and mRNAs of PSD95 and SYP. CONCLUSION: QFY could effectively improve the learning and memory impairment of D-gal-induced AD mice by inhibiting the excessive activation of microglia, enhancing the expression of M2 microglia, inhibiting the increase of inflammatory factors, cell adhesion factors and chemokines, anti-apoptosis, and improving synaptic plasticity. Dove 2023-09-14 /pmc/articles/PMC10506672/ /pubmed/37727255 http://dx.doi.org/10.2147/DDDT.S402624 Text en © 2023 Lei et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lei, Xia Xu, Hongdan Wang, Yan Gao, Hainan Zhao, Deping Zhang, Jinfeng Zhu, Ziyue Zuo, Kun Liu, Ying Li, Xiaoliang Zhang, Ning Integrating Network Pharmacology and Component Analysis to Study the Potential Mechanisms of Qi-Fu-Yin Decoction in Treating Alzheimer’s Disease |
title | Integrating Network Pharmacology and Component Analysis to Study the Potential Mechanisms of Qi-Fu-Yin Decoction in Treating Alzheimer’s Disease |
title_full | Integrating Network Pharmacology and Component Analysis to Study the Potential Mechanisms of Qi-Fu-Yin Decoction in Treating Alzheimer’s Disease |
title_fullStr | Integrating Network Pharmacology and Component Analysis to Study the Potential Mechanisms of Qi-Fu-Yin Decoction in Treating Alzheimer’s Disease |
title_full_unstemmed | Integrating Network Pharmacology and Component Analysis to Study the Potential Mechanisms of Qi-Fu-Yin Decoction in Treating Alzheimer’s Disease |
title_short | Integrating Network Pharmacology and Component Analysis to Study the Potential Mechanisms of Qi-Fu-Yin Decoction in Treating Alzheimer’s Disease |
title_sort | integrating network pharmacology and component analysis to study the potential mechanisms of qi-fu-yin decoction in treating alzheimer’s disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506672/ https://www.ncbi.nlm.nih.gov/pubmed/37727255 http://dx.doi.org/10.2147/DDDT.S402624 |
work_keys_str_mv | AT leixia integratingnetworkpharmacologyandcomponentanalysistostudythepotentialmechanismsofqifuyindecoctionintreatingalzheimersdisease AT xuhongdan integratingnetworkpharmacologyandcomponentanalysistostudythepotentialmechanismsofqifuyindecoctionintreatingalzheimersdisease AT wangyan integratingnetworkpharmacologyandcomponentanalysistostudythepotentialmechanismsofqifuyindecoctionintreatingalzheimersdisease AT gaohainan integratingnetworkpharmacologyandcomponentanalysistostudythepotentialmechanismsofqifuyindecoctionintreatingalzheimersdisease AT zhaodeping integratingnetworkpharmacologyandcomponentanalysistostudythepotentialmechanismsofqifuyindecoctionintreatingalzheimersdisease AT zhangjinfeng integratingnetworkpharmacologyandcomponentanalysistostudythepotentialmechanismsofqifuyindecoctionintreatingalzheimersdisease AT zhuziyue integratingnetworkpharmacologyandcomponentanalysistostudythepotentialmechanismsofqifuyindecoctionintreatingalzheimersdisease AT zuokun integratingnetworkpharmacologyandcomponentanalysistostudythepotentialmechanismsofqifuyindecoctionintreatingalzheimersdisease AT liuying integratingnetworkpharmacologyandcomponentanalysistostudythepotentialmechanismsofqifuyindecoctionintreatingalzheimersdisease AT lixiaoliang integratingnetworkpharmacologyandcomponentanalysistostudythepotentialmechanismsofqifuyindecoctionintreatingalzheimersdisease AT zhangning integratingnetworkpharmacologyandcomponentanalysistostudythepotentialmechanismsofqifuyindecoctionintreatingalzheimersdisease |